ATE427106T1 - Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma. - Google Patents

Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.

Info

Publication number: ATE427106T1
Authority: AT; Austria
Prior art keywords: sphingolipids; cholesterol; triglyceride; triglyceride levels; plasma cholesterol
Prior art date: 2003-01-20

Application number

AT04703544T

Other languages

English (en)

Inventor

Willem Nieuwenhuizen

Original Assignee

Tno

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-20

Filing date

2004-01-20

Publication date

2009-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32773655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE427106(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-01-20 Priority claimed from NL1022442A external-priority patent/NL1022442C2/nl

2004-01-20 Application filed by Tno filed Critical Tno

2009-04-15 Application granted granted Critical

2009-04-15 Publication of ATE427106T1 publication Critical patent/ATE427106T1/de

Links

HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 9
150000003408 sphingolipids Chemical class 0.000 title abstract 4
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title abstract 4
235000012000 cholesterol Nutrition 0.000 abstract 2
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 abstract 1
JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 abstract 1
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 abstract 1
AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 abstract 1
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 abstract 1
229940106189 ceramide Drugs 0.000 abstract 1
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 abstract 1
229930183167 cerebroside Natural products 0.000 abstract 1
RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 abstract 1
OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 abstract 1
235000013305 food Nutrition 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 abstract 1
AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 abstract 1
229940033329 phytosphingosine Drugs 0.000 abstract 1
OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 abstract 1
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 abstract 1
239000013589 supplement Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/40—Effervescence-generating compositions
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Nutrition Science (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

AT04703544T 2003-01-20 2004-01-20 Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma. ATE427106T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL1022442A NL1022442C2 (nl)	2003-01-20	2003-01-20	Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen.
EP03078141		2003-10-06

Publications (1)

Publication Number	Publication Date
ATE427106T1 true ATE427106T1 (de)	2009-04-15

Family

ID=32773655

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04703544T ATE427106T1 (de)	2003-01-20	2004-01-20	Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.

Country Status (7)

Country	Link
US (1)	US7968529B2 (de)
EP (1)	EP1585508B1 (de)
JP (1)	JP2006516280A (de)
AT (1)	ATE427106T1 (de)
DE (1)	DE602004020316D1 (de)
ES (1)	ES2325260T3 (de)
WO (1)	WO2004064820A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004064820A2 (en)	2003-01-20	2004-08-05	Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno	Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels
NL1022443C2 (nl)	2003-01-20	2004-07-22	Tno	Sphingolipiden voor verbetering van de samenstelling van de darmflora.
US20050196461A1 (en) *	2004-01-14	2005-09-08	Udell Ronald G.	Ceramide formulations suitable for oral administration
JP5154218B2 (ja) *	2004-03-16	2013-02-27	ネーデルランドセオルガニサティエフォールトエゲパスト−ナトールヴェテンシャッペリクオンデルゾエクティエヌオー	２型糖尿病、インスリン抵抗性及びメタボリック症候群の治療及び予防においてスフィンゴ脂質を使用する方法
JP4359204B2 (ja) *	2004-03-19	2009-11-04	花王株式会社	皮膚保湿用食品
EP1618876A1 (de) *	2004-07-19	2006-01-25	Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO	Verwendung von Sphingolipiden zur Vorbeugung und Behandlung von Atherosklerose
US7648714B2 (en)	2004-08-05	2010-01-19	Kao Corporation	Food for skin moisture retention
DE102004052697A1 (de) *	2004-10-29	2006-05-04	Haehner, Thomas, Dr.	Pharmazeutische Zubereitungen zur Behandlung von Folgen des Alkoholmissbrauchs, Hepatitis, Pankreatitis, Alzheimererkrankung, Morbus Parkinson, Diabetes, toxischen Nierenerkrankungen, Reperfusionsschäden, der Arteriosklerose sowie als Antidote gegen Umweltgifte und Medikamentenintoxikation
ATE539741T1 (de) *	2004-11-30	2012-01-15	Tno	Sphingolipide bei der behandlung und prävention von hepatischer steatose
JP4040069B2 (ja) *	2005-08-09	2008-01-30	株式会社ミツカングループ本社	脳機能改善用組成物
JP2008013579A (ja) *	2005-08-22	2008-01-24	Mitsukan Group Honsha:Kk	筋肉損傷抑制組成物
JP4040070B2 (ja) *	2005-08-22	2008-01-30	株式会社ミツカングループ本社	筋肉損傷抑制組成物
NZ566842A (en)	2005-09-22	2011-12-22	Megmilk Snow Brand Co Ltd	Use of sphingomyelin for preventing or reducing alcohol intoxication and/or hangover
EP1815745A1 (de)	2006-02-03	2007-08-08	Friesland Brands B.V.	Cholesterinsenkende Milchprodukte und Verfahren zu deren Herstellung
NZ601174A (en) *	2006-04-07	2013-10-25	Megmilk Snow Brand Co Ltd	Fat accumulation inhibitor
TWI589228B (zh)	2009-04-23	2017-07-01	S A Corman	降低膽固醇含量之奶產品
JP5689055B2 (ja) *	2009-05-13	2015-03-25	丸大食品株式会社	鳥皮由来スフィンゴミエリン含有物を有効成分とする抗高血糖及び／又は抗高脂血症剤
US10227290B2 (en)	2012-02-07	2019-03-12	The Regents Of The University Of California	Glycosphingolipids for use in modulating immune responses
US10329315B2 (en)	2012-10-12	2019-06-25	The Brigham And Women's Hospital, Inc.	Glycosphingolipids and methods of use thereof
JP2016013083A (ja) *	2014-07-01	2016-01-28	花王株式会社	麺つゆ
JP6232008B2 (ja) *	2015-03-19	2017-11-15	国立大学法人北海道大学	酸化抑制剤及びこれを用いた油脂含有飲食品
US20170044516A1 (en)	2015-08-11	2017-02-16	Industrial Technology Research Institute	Biochemistry reactive material and device for eliminating electronegative low-density lipoprotein (ldl) and method for treating blood or plasma ex vivo to eliminate electronegative low-density lipoprotein therein

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2492259A1 (fr)	1980-10-21	1982-04-23	Idinvex Sa	Formulation d'heparine
JPS61152632A (ja)	1984-12-26	1986-07-11	Dai Ichi Seiyaku Co Ltd	抗動脈硬化剤
JPS6344842A (ja)	1986-08-12	1988-02-25	Kao Corp	油中水中油型乳化油脂組成物
US4952567A (en) *	1988-05-09	1990-08-28	City Of Hope	Inhibition of lipogenesis
IT1235162B (it) *	1988-12-02	1992-06-22	Fidia Farmaceutici	Derivati di lisosfingolipidi
US5190876A (en)	1988-12-27	1993-03-02	Emory University	Method of modifying cellular differentiation and function and compositions therefor
US5231090A (en) *	1990-07-30	1993-07-27	University Of Miami	Treatment for hypercholesterolemia
EP0543922A4 (en)	1990-08-13	1993-07-28	Duke University	Methods for inducing cell differentiation using ceramides
US5543390A (en)	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Covalent microparticle-drug conjugates for biological targeting
US5232837A (en)	1991-08-05	1993-08-03	Emory University	Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination
US5374616A (en)	1991-10-18	1994-12-20	Georgetown University	Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
US6190894B1 (en)	1993-03-19	2001-02-20	The Regents Of The University Of California	Method and compositions for disrupting the epithelial barrier function
US5478860A (en)	1993-06-04	1995-12-26	Inex Pharmaceuticals Corp.	Stable microemulsions for hydrophobic compound delivery
US5830853A (en)	1994-06-23	1998-11-03	Astra Aktiebolag	Systemic administration of a therapeutic preparation
US6773719B2 (en) *	1994-03-04	2004-08-10	Esperion Luv Development, Inc.	Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US20020182250A1 (en)	1995-09-06	2002-12-05	Goro Hori	Lipid metabolism improving agent
US5714478A (en)	1995-09-29	1998-02-03	Spiegel; Sarah	Sphingosylphosphorylcholine as a wound-healing agent
DE19602108A1 (de)	1996-01-22	1997-07-24	Beiersdorf Ag	Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Substanzen
WO1997030174A1 (en)	1996-02-20	1997-08-21	Sloan-Kettering Institute For Cancer Research	Combinations of pkc inhibitors and therapeutic agents for treating cancers
CN1222293C (zh)	1997-04-10	2005-10-12	麒麟麦酒株式会社	含有α－糖基神经酰胺的NKT细胞活化剂
US6800661B1 (en)	1997-04-15	2004-10-05	Board Of Trustees Of The University Of Illinois	Spisulosine compounds
US5989803A (en)	1997-09-05	1999-11-23	The Trustees Of Columbia University In The City Of New York	Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
US6610835B1 (en)	1998-02-12	2003-08-26	Emory University	Sphingolipid derivatives and their methods of use
JP3581010B2 (ja)	1998-03-18	2004-10-27	雪印乳業株式会社	脂質の消化吸収機能改善剤
CA2329124A1 (en)	1998-05-26	1999-12-02	Office Of The Dean Of Research And Graduate Education	Sphingosine kinase, cloning, expression and methods of use
US6713057B1 (en) *	1999-02-24	2004-03-30	The Johns Hopkins University	Compositions and methods for modulating serum cholesterol
WO2000050574A1 (en) *	1999-02-24	2000-08-31	Johns Hopkins University	Compositions and methods for modulating serum cholesterol
JP3544493B2 (ja) *	1999-06-10	2004-07-21	雪印乳業株式会社	乳幼児用栄養組成物
KR100341793B1 (ko)	1999-07-02	2002-06-24	권 영 근	스핑고신 1-포스페이트를 유효성분으로 포함하는 혈관신생 촉진제
WO2001003739A1 (fr)	1999-07-12	2001-01-18	Ono Pharmaceutical Co., Ltd.	Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
JP2001213858A (ja)	1999-11-24	2001-08-07	Sagami Chem Res Center	スフィンゴシン誘導体
JP2001158736A (ja) *	1999-11-30	2001-06-12	Snow Brand Milk Prod Co Ltd	骨関節疾患の予防及び改善剤
JP2001158735A (ja)	1999-11-30	2001-06-12	Snow Brand Milk Prod Co Ltd	歯周病の予防及び改善剤
WO2001060807A1 (en)	2000-02-18	2001-08-23	Merck & Co. Inc.	Aryloxyacetic acids for diabetes and lipid disorders
EP1268414A1 (de)	2000-03-28	2003-01-02	The Liposome Company, Inc.	Ceramid-derivate und verwendungsmethode
JP2002068998A (ja)	2000-08-29	2002-03-08	Meiji Milk Prod Co Ltd	経腸栄養および静脈栄養に伴う脂肪肝発生予防組成物
AU2001212597A1 (en)	2000-10-27	2002-05-06	N.V. Marc Boone	Method for obtaining products enriched in phospho- and sphingolipids
WO2002042698A1 (en) *	2000-11-22	2002-05-30	Kc & Aa, Inc.	Portable cooler for beverage container
US6949247B2 (en)	2000-12-28	2005-09-27	Unilever Home & Personal Care Usa Division Of Conopco, Inc.	Stable skin care compositions containing a retinoid and a retinoid booster system
FR2820037B1 (fr)	2001-01-29	2005-12-09	Dermaconcept Jmc	Composition dermatologique a usage veterinaire comprenant une base sphingoide
JP2002226394A (ja) *	2001-02-01	2002-08-14	Meiji Milk Prod Co Ltd	脂質代謝改善組成物
JP4958339B2 (ja) *	2001-03-21	2012-06-20	雪印メグミルク株式会社	脂質代謝改善剤
ATE554779T1 (de)	2001-06-18	2012-05-15	Neptune Technologies & Bioressources Inc	Krill zur prävention und/oder behandlung von herz-kreislauf-erkrankungen
US8030348B2 (en)	2001-07-27	2011-10-04	Neptune Technologies & Bioressources, Inc.	Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications
EP1291340B1 (de)	2001-09-05	2006-03-15	Charmzone Co., Ltd	Phytosphingosinderivate mit Antitumorwirkung
US20030109044A1 (en)	2001-10-16	2003-06-12	Millennium Pharmaceuticals, Inc.	Methods of using 279, a human G protein-coupled protein receptor
JP4035759B2 (ja)	2001-11-06	2008-01-23	独立行政法人産業技術総合研究所	アミノアルコールリン酸化合物、製造方法、及びその利用方法
DE10217555A1 (de)	2002-04-19	2004-02-19	Degussa Bioactives Deutschland Gmbh	Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix
JP2006507223A (ja)	2002-05-17	2006-03-02	エスペリオンセラピューティクス，インコーポレイテッド	脂質代謝異常疾患の治療方法
AU2002349521A1 (en)	2002-08-14	2004-03-03	Tae-Yoon Kim	A composition comprising phytospingosine derivatives for apoptosis induction
WO2004064820A2 (en)	2003-01-20	2004-08-05	Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno	Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels
NL1022443C2 (nl)	2003-01-20	2004-07-22	Tno	Sphingolipiden voor verbetering van de samenstelling van de darmflora.
GB0301395D0 (en)	2003-01-21	2003-02-19	Univ Aston	Inflammatory disorder treatment
US9717754B2 (en)	2003-02-27	2017-08-01	Enzo Therapeutics, Inc.	Glucocerebroside treatment of disease
US20040171522A1 (en)	2003-02-27	2004-09-02	Yaron Ilan	Regulation of immune responses by manipulation of intermediary metabolite levels
EP1617808A4 (de)	2003-04-25	2011-11-02	Penn State Res Found	Verfahren und system für die systemische abgabe von wachstumshemmenden von lipiden stammenden bioaktiven verbindungen

2004
- 2004-01-20 WO PCT/NL2004/000048 patent/WO2004064820A2/en not_active Ceased
- 2004-01-20 EP EP04703544A patent/EP1585508B1/de not_active Revoked
- 2004-01-20 DE DE602004020316T patent/DE602004020316D1/de not_active Expired - Lifetime
- 2004-01-20 ES ES04703544T patent/ES2325260T3/es not_active Expired - Lifetime
- 2004-01-20 AT AT04703544T patent/ATE427106T1/de not_active IP Right Cessation
- 2004-01-20 US US10/542,845 patent/US7968529B2/en not_active Expired - Fee Related
- 2004-01-20 JP JP2006500735A patent/JP2006516280A/ja active Pending

Also Published As

Publication number	Publication date
ES2325260T3 (es)	2009-08-31
WO2004064820A2 (en)	2004-08-05
JP2006516280A (ja)	2006-06-29
EP1585508B1 (de)	2009-04-01
WO2004064820A3 (en)	2004-09-30
EP1585508A2 (de)	2005-10-19
DE602004020316D1 (de)	2009-05-14
US7968529B2 (en)	2011-06-28
US20060189575A1 (en)	2006-08-24

Legal Events

Date	Code	Title	Description
2009-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE427106T1 (de)	2009-04-15	Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.
Moore et al.	2017	The chemistry, function and (patho) physiology of stratum corneum barrier ceramides
Pope et al.	2008	Oxidative stress and mitochondrial dysfunction in neurodegeneration; cardiolipin a critical target?
Kato-Kataoka et al.	2010	Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints
MY172306A (en)	2019-11-21	Use of nutritional compositions with phospholipid, sphingolipid and cholesterol
MY155710A (en)	2015-11-13	Composition for regulating lipid metabolism
Moon et al.	2013	Altered levels of sphingosine and sphinganine in psoriatic epidermis
BR112013028440A2 (pt)	2016-11-29	composições e métodos que compreendem variantes de serina protease
BRPI0609393B8 (pt)	2021-05-25	usos de um composto 11-desóxi-prostaglandina
ATE539751T1 (de)	2012-01-15	Verwendung von brimonidine zur behandlung von stress assoziierten zuständen
MY161991A (en)	2017-05-31	Proteasome inhibitors
Afanas’ ev	2005	Free radical mechanisms of aging processes under physiological conditions
WO2005099716A3 (en)	2005-12-22	Method for analyzing the biological age of a subject
Molano et al.	2012	Age-dependent changes in the sphingolipid composition of mouse CD4+ T cell membranes and immune synapses implicate glucosylceramides in age-related T cell dysfunction
JP2006516280A5 (de)	2007-03-01
EP2065040A3 (de)	2009-09-09	Von Sphingolipiden abgeleitete pharmazeutische Zusammensetzungen
Kong et al.	2009	Sesamin improves endothelial dysfunction in renovascular hypertensive rats fed with a high-fat, high-sucrose diet
Ferreira et al.	2010	Sphingomyelinase stimulates oxidant signaling to weaken skeletal muscle and promote fatigue
Sugawara et al.	2004	Efflux of sphingoid bases by P-glycoprotein in human intestinal Caco-2 cells
Reichel et al.	2015	Alterations of plasma glycerophospholipid and sphingolipid species in male alcohol-dependent patients
Schiffmann et al.	2012	Inhibitors of specific ceramide synthases
GT200600115A (es)	2006-11-29	Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal
Kuo et al.	2022	Murine endothelial serine palmitoyltransferase 1 (SPTLC1) is required for vascular development and systemic sphingolipid homeostasis
DE602004016727D1 (de)	2008-11-06	Sphingolipiden zur verbesserung der darmflorazusammensetzung
WO2003048784A3 (en)	2003-12-18	Internal standards for sphingolipids for use in mass spectrometry